摘要
目的:探讨罗格列酮减少糖尿病肾病患者蛋白尿的疗效。方法:120例糖尿病肾病患者按蛋白尿定性分为轻度(±～+)32例、中度(++)48例、重度(+++～++++)40例共3组,每组又平均分为观察组和对照组,分别予ACEI/ARB及ACEI/ARB联合罗格列酮治疗,疗程6个月,观察两组蛋白尿减少程度及减少时间。结果:观察组患者尿蛋白下降程度较对照组患者显著(P<0.05或P<0.01),而且尿蛋白下降人数达观察人数的半数所需时间均明显短于对照组(P<0.01)。结论:罗格列酮能显著降低糖尿病肾病患者蛋白尿程度,并能减少蛋白尿转阴时间。
Objective：To observe the effect of rosiglitazone on albuminuria reduction in diabetic nephropathy patients. Methods： 120 patients of diabetic nephropathy were divided into three groups by urine protein level. Each group was randomized into ACEI/ARB treatment group and rosiglitazone ＋ ACEI/ARB treatment group. All patients were followed up half years to observe the time and degree of albuminuria reduction. Results：Both ACEI/ARB treatment and rosiglitazone＋ ACEI/ARB treatment could lead protein in urine disappear in diabetic nephropathy patients with mild albuminuria. Rosiglitazone＋ ACEI/ARB treatment could shorten the time of albuminuria reduction significantly. Conclusions： Rosiglitazonean could shorten the time of albuminuria reduction in diabetic nephropathy patients when used with ACEI/ARB.
出处
《中国冶金工业医学杂志》
2009年第3期263-264,共2页
Chinese Medical Journal of Metallurgical industry
关键词
糖尿病肾病
蛋白尿
罗格列酮
Diabetic nepbropathy
Albuminuria
Rosiglitazone
